Arkolith/Insider Trading/QNCX/Form 4

Hannah Brendan

Chief Business OfficerQuince Therapeutics, Inc. (QNCX) · full profile →Form 4 · filed Aug 9, 2023
Net Buying
Open-Market Buys
$88K
Open-Market Sells
$0
Net Open-Market Flow
$88K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Aug 8, 2023Buy(P)72K$1.22$88K202K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-23-045234) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML